# A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration

> **NCT00395057** · PHASE2 · TERMINATED · sponsor: **Allergan** · enrollment: 138 (actual)

## Conditions studied

- Choroid Neovascularization
- Age-Related Macular Degeneration

## Interventions

- **DRUG:** AGN 211745
- **DRUG:** AGN 211745
- **DRUG:** AGN 211745
- **DRUG:** Ranibizumab 500µg

## Key facts

- **NCT ID:** NCT00395057
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-01
- **Primary completion:** 2008-10
- **Final completion:** 2009-02
- **Target enrollment:** 138 (ACTUAL)
- **Why stopped:** The study was terminated early due to company decision (non-safety related).
- **Last updated:** 2015-09-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00395057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00395057, "A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration". Retrieved via MORVS 2026-10-23 from https://api.morvs.ai/clinical/NCT00395057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*